Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (7): 658-668.doi: 10.19982/j.issn.1000-6621.20230057
• Original Articles • Previous Articles Next Articles
Zheng Rui1,2, Zhao Mingrui1, Yang Yuanzheng1()
Received:
2023-02-28
Online:
2023-07-10
Published:
2023-06-29
Contact:
Yang Yuanzheng, Email: CLC Number:
Zheng Rui, Zhao Mingrui, Yang Yuanzheng. Meta-analysis of effectiveness and safety of the cycloserine-containing treatment for multidrug-resistant pulmonary tuberculosis in China[J]. Chinese Journal of Antituberculosis, 2023, 45(7): 658-668. doi: 10.19982/j.issn.1000-6621.20230057
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20230057
文献来源 | 患者总数 (例,T/C) | 干预措施 | 结局指标 | |||||
---|---|---|---|---|---|---|---|---|
对照组 | 研究组 | |||||||
邹乔2022[ | 96(48/48) | 6个月Z、Am、Lfx、E、Pto;12个月Lfx、Pto | 在对照组基础上加用Cs | ①②③⑤ | ||||
彭娜2021[ | 76(38/38) | 1阶段:Z、Am、Lfx、Pto、E;2阶段:Z、Lfx、E、Pto,共1年 | 在对照组基础上加用Cs | ②⑤ | ||||
苏丽明2022[ | 84(42/42) | 6个月Rfb、Mfx、Pto、Z;18个月口服Rfb、Mfx、Pto、Z、PAS | 在对照组基础上口服Cs | ② | ||||
徐俊彦2019[ | 48(24/24) | 6个月Rfb、Mfx、Pto、Z、Am、PAS;18个月Rfb、Mfx、Pto、Z、PAS | 在对照组基础上口服Cs | ①②⑤ | ||||
何建2015[ | 36(18/18) | 6个月Z、Km、Lfx、Pto、PAS;18个月非注射期,每周用药6次 | 在对照组基础上口服Cs | ①②③⑤ | ||||
谷崇峰2020[ | 50(25/25) | Z、Lzd、E、Pto跟踪观察9个月 | 在对照组基础上口服Cs | ①②⑤ | ||||
巴桑拉姆2020[ | 90(45/45) | 8个月Z、A、Lfx、Pto、Cs;18个月Z、Lfx、Pto | 研究组在对照组基础上,于第二阶段加用Cs | ①⑤ | ||||
梁威2020[ | 50(25/25) | Z、Lfx、E、Pto跟踪观察半年 | 在对照组基础上口服Cs | ①⑤ | ||||
张德利2019[ | 70(35/35) | 20个月Z、Lfx、E、Pto | 在对照组基础上口服Cs | ④ | ||||
杨丽娜2018[ | 124(62/62) | 一阶段:Z、Lfx、Pto、E;二阶段:Z、Mfx、Pto、E共24个月 | 在对照组基础上口服Cs | ①⑤ | ||||
刘政2020[ | 68(34/34) | 18个月含Mfx的治疗方案 | 在对照组基础上口服Cs | ②⑤ | ||||
韩莉2018[ | 120(60/60) | 20个月巩固期:Z、Am、Mfx、Pto、PAS | 在对照组基础上口服Cs | ①④⑤ | ||||
杨蒙2022[ | 60(30/30) | E、Pto、Am、Z、Lfx,跟踪观察6个月 | 在对照组基础上口服Cs | ①②⑤ | ||||
宫俐2018[ | 96(48/48) | Rft、Cs、PAS、Mfx跟踪观察9个月 | 在对照组基础上口服Cs | ①②⑤ | ||||
王华2020[ | 58(29/29) | Z、Cs/Am、Lfx/Mfx、Pto跟踪观察>8个月 | 在对照组基础上口服Cs | ①⑤ | ||||
何飞歌2020[ | 82(41/41) | 6个月Z、Cs、Lfx、Pto;18个月Z、Lfx、Pto | 在对照组基础上加用Cs、胸腺肽肠溶片 | ② | ||||
吴小霞2016[ | 60(30/30) | 6个月Z、Cs/Am、Lfx/Mfx、Pto;18个月Z、Lfx/Mfx、Pto | 在对照组基础上加用Cs、胸腺肽 | ①②③ | ||||
张喜平2019[ | 92(46/46) | 6个月Z、K、Lfx、Pto、PAS;18个月Z、Lfx、Pto、PAS | 在对照组基础上加用Cs、胸腺肽 | ①②③⑤ | ||||
肖海凤2021[ | 69(34/35) | 24个月常规耐多药治疗方案 | 在对照组基础上加用Cs、胸腺肽 | ①②③ | ||||
林武振2017[ | 50(25/25) | 12个月Z、K、Lfx、Pto、PAS | 在对照组基础上加用Cs、胸腺肽 | ① | ||||
刘伯飞2020[ | 130(70/60) | Z、Cs、Lfx、Pto、PAS跟踪观察12个月 | 在对照组基础上加用Cs、胸腺肽 | ① | ||||
杨俭2018[ | 56(28/28) | 24个月Z、K、Mfx、Pto、PAS | 在对照组基础上加用Cs、胸腺肽 | ①②③ | ||||
韩红燕2022[ | 90(45/45) | 6个月Z、Cs/Am、Lfx/Mfx、Pto;18个月Z、Lfx/Mfx、Pto | 在对照组基础上加用Cs、胸腺肽肠溶片口服 | ①②③⑤ | ||||
周璐2019[ | 80(40/40) | 6个月Z、Cs/Am、Lfx/Mfx、Pto;18个月Z、Lfx/Mfx、Pto | 在对照组基础上加用Cs、胸腺肽肠溶片 | ④⑤ | ||||
陈永宏2019[ | 82(41/41) | 6个月Z、A、Lfx/Mfx、Pto、PAS;18个月Z、Lfx/Mfx、Pto、PAS | 在对照组基础上加用Cs、胸腺肽肠溶片 | ①②③⑤ | ||||
王琳琳2020[ | 78(39/39) | 6个月Z、Cs/Am、Mfx/Lfx、Pto;18个月Z、Mfx/Lfx、Pto;在上述方案加用PAS | 将对照组的PAS更换为Cs,其余同对照组 | ①⑤ | ||||
邹广顺2018[ | 98(49/49 | 6个月Z、A、Lfx、Pto;18个月Z、Lfx、Pto;在上述方案加用PAS | 将对照组的PAS更换为Cs,其余同对照组 | ①⑤ | ||||
曹海峰2017[ | 34(17/17) | 6个月K、Lfx、Pto、Z;18个月Lfx、Pto、Z;上述方案加用PAS | 将对照组的PAS更换为Cs,其余同对照组 | ①②③ | ||||
陈春玲2018[ | 134(67/67) | 6个月Z、Cs/Am、Lfx/Mfx、Pto;18个月Z、Lfx/Mfx、Pto;在上述方案加用PAS | 将对照组的PAS更换为Cs,其余同对照组 | ① | ||||
裴洁2015[ | 98(50/48) | 6个月Z、Cs/Am、Lfx/Mfx、Pto;18个月Z、Lfx/Mfx、Pto;在上述方案加用PAS | 将对照组的PAS更换为Cs,其余同对照组 | ①⑤ | ||||
明磊2020[ | 66(33/33) | 24个月标准抗结核治疗方案上加用E | 将对照组的E更换为Cs | ①⑤ | ||||
谢舒枝2018[ | 96(48/48) | 第一阶段Z、Lfx、Pto;第二阶段Z、Mfx、Pto共24个月;上述方案加用E | 将对照组的E更换为Cs,其余同对照组 | ①⑤ | ||||
邹洪强2021[ | 94(47/47) | 6个月强化期Z、A、Lfx、Pto;18个月巩固期Z、Lfx、Pto用量同前;上述方案加用E | 将对照组的E更换为Cs,其余同对照组 | ①②③⑤ | ||||
彭章丽2018[ | 68(34/34) | 6个月Z、Km、Lfx、Pto、E;18个月Z、Lfx、Pto、E | 6个月Z-Km-Lfx-Pto-Cs/18个月Z-Lfx-Pto-Cs | ②⑤ | ||||
沈莉莉2017[ | 95(49/46) | 治疗方案:Z、Am、Lfx、Pto跟踪观察18个月;上述治疗加用E | 将对照组的E更换为Cs,其余同对照组 | ①③⑤ |
分组 | 研究设计 | 患者总例数 (T/C) | 关联性检验 | 异质性检验 | |||
---|---|---|---|---|---|---|---|
RR(95%CI)值 | P值 | I2值(%) | P值 | ||||
A | “Cs+常规治疗”对比“常规治疗” | 1128(565/563) | 2.230(1.695~2.934) | <0.001 | 0.00 | 0.994 | |
B | “胸腺肽+Cs+常规治疗”对比“常规治疗” | 791(400/391) | 2.595(1.861~3.619) | <0.001 | 0.00 | 0.857 | |
C | “Cs+常规治疗”对比“PAS+常规治疗” | 433(219/214) | 1.689(1.125~2.535) | 0.011 | 0.00 | 0.968 | |
D | “Cs+常规治疗”对比“E+常规治疗” | 419(211/208) | 3.250(2.310~4.570) | <0.001 | 4.70 | 0.380 |
干预措施 | 关联性检验 | 异质性检验 | 数据合并模型 | ||
---|---|---|---|---|---|
RR(95%CI)值 | P值 | I2值(%) | P值 | ||
用药前是否对患者精神神经系统疾病状态筛查 | 随机效应模型 | ||||
是 | 1.574(1.190~2.084) | <0.001 | 52.80 | 0.038 | |
否 | 1.556(1.277~1.896) | <0.001 | 44.10 | 0.050 | |
是否按体质量调整环丝氨酸剂量(去除2篇调整用量剂量不详文献) | 固定效应模型 | ||||
是 | 1.573(1.150~2.151) | 0.005 | 46.60 | 0.069 | |
否 | 1.570(1.229~2.005) | <0.001 | 27.90 | 0.188 | |
是否同时应用维生素B6进行不良反应的预防 | 随机效应模型 | ||||
是 | 1.405(0.987~2.002) | 0.059 | 68.60 | 0.001 | |
否 | 1.411(1.138~1.749) | 0.002 | 0.00 | 0.818 |
[1] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
[2] |
王胜芬, 周杨, 欧喜超, 等. 我国结核病耐药状况:2018年全国结核病耐药监测数据分析. 中国防痨杂志, 2022, 44(11):1141-1147. doi:10.19982/j.issn.1000-6621.20220268.
doi: 10.19982/j.issn.1000-6621.20220268 |
[3] |
首都医科大学附属北京胸科医院, 中国防痨协会临床试验专业分会, 《中国防痨杂志》编辑委员会. 环丝氨酸治疗结核病的临床用药指南. 中国防痨杂志, 2020, 42(6):533-540. doi:10.3969/j.issn.1000-6621.2020.06.001.
doi: 10.3969/j.issn.1000-6621.2020.06.001 |
[4] |
Chirehwa MT, Court R, de Kock M, et al. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrob Agents Chemother, 2020, 64(11):e01381-20. doi:10.1128/AAC.01381-20.
doi: 10.1128/AAC.01381-20 |
[5] |
Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. Clin Infect Dis, 2022, 75(4):682-689. doi:10.1093/cid/ciab992.
doi: 10.1093/cid/ciab992 URL |
[6] |
Gao W, Yang N, Mei X, et al. Influence of anti-tuberculosis drugs plus cycloserine on sputum negative conversion rate, adverse reactions and inflammatory factors in multi-drug resistant tuberculosis. Am J Transl Res, 2021, 13(8):9332-9339.
pmid: 34540050 |
[7] |
Chen J, Zhang S, Cui P, et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2017, 72(12):3272-3276. doi:10.1093/jac/dkx316.
doi: 10.1093/jac/dkx316 URL |
[8] |
Wang J, Pang Y, Jing W, et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist, 2019, 12:763-770. doi:10.2147/IDR.S194484.
doi: 10.2147/IDR.S194484 pmid: 31040707 |
[9] |
邹乔, 王芳芳. 含环丝氨酸化疗方案治疗耐多药肺结核患者的效果. 中国民康医学, 2022, 29(15):36-42. doi:10.3969/j.issn.1672-0369.2022.15.011.
doi: 10.3969/j.issn.1672-0369.2022.15.011 |
[10] |
彭娜, 唐蜜. 含环丝氨酸治疗方案治疗耐多药肺结核病的临床疗效. 临床合理用药杂志, 2021, 14(18):102-104. doi:10.15887/j.cnki.13-1389/r.2021.18.037.
doi: 10.15887/j.cnki.13-1389/r.2021.18.037 |
[11] |
苏丽明. 含Cs化疗方案治疗耐多药肺结核患者的效果分析. 中国现代药物应用, 2022, 16(4):151-154. doi:10.14164/j.cnki.cn11-5581/r.2022.04.058.
doi: 10.14164/j.cnki.cn11-5581/r.2022.04.058 |
[12] |
徐俊彦, 钟凯惠, 薛卫, 等. 含环丝氨酸结核方案治疗耐多药肺结核病患者疗效及安全性. 中华生物医学工程杂志, 2019, 25(1):108-111. doi:10.3760/cma.j.issn.1674-1927.2019.01.021.
doi: 10.3760/cma.j.issn.1674-1927.2019.01.021 |
[13] | 何建, 李剑华, 罗世珍. 含环丝氨酸方案治疗耐多药肺结核18例. 中国药业, 2015, 24(7):124-126. |
[14] |
谷崇峰. 环丝氨酸联合抗结核药物对耐多药肺结核的临床治疗有效性、安全性观察. 实用妇科内分泌电子杂志, 2020, 7(10):133-134. doi:10.16484/j.cnki.issn2095-8803.2020.10.086.
doi: 10.16484/j.cnki.issn2095-8803.2020.10.086 |
[15] | 巴桑拉姆. 环丝氨酸联合抗结核药物对耐多药肺结核的临床治疗有效性,安全性观察. 临床医药文献电子杂志, 2020, 7(55):152,155. |
[16] | 梁威. 环丝氨酸联合抗结核药物治疗耐多药肺结核的疗效及安全性. 临床医药文献电子杂志, 2020, 7(A2):156,159. |
[17] | 张德利, 张彦. 环丝氨酸联合抗结核药物治疗耐多药肺结核的疗效及安全性. 养生保健指南, 2019, 18(50):223. |
[18] |
杨丽娜. 环丝氨酸配合抗结核药物治疗耐多药肺结核疗效及安全性评价. 医药前沿, 2018, 8(30):48-49. doi:10.3969/j.issn.2095-1752.2018.30.036.
doi: 10.3969/j.issn.2095-1752.2018.30.036 |
[19] | 刘政. 抗结核药物结合环丝氨酸治疗耐多药肺结核的效果和安全性分析. 母婴世界, 2020, 20(7):105. |
[20] |
韩莉. 莫西沙星联合环丝氨酸治疗耐多药肺结核的临床疗效. 实用心脑肺血管病杂志, 2018, 26(4):136-138. doi:10.3969/j.issn.1008-5971.2018.04.036.
doi: 10.3969/j.issn.1008-5971.2018.04.036 |
[21] | 杨蒙. 环丝氨酸联合抗结核药物治疗耐多药肺结核的临床效果研究. 中华养生保健, 2022, 40(18):154-157. |
[22] | 宫俐, 韩中波. 莫西沙星联合环丝氨酸治疗耐多药肺结核的临床研究. 健康之路, 2018, 17(9):102. |
[23] | 王华. 环丝氨酸联合抗结核药物对耐多药肺结核的临床治疗有效性、安全性观察. 大健康, 2020, 21(18):163,166. |
[24] |
何飞歌, 吕海珍. 环丝氨酸胶囊联合胸腺肽肠溶片治疗耐多药肺结核的临床效果. 临床医学研究与实践, 2020, 5(5):41-43. doi:10.19347/j.cnki.2096-1413.202005017.
doi: 10.19347/j.cnki.2096-1413.202005017 |
[25] | 吴小霞, 辛朝雄, 杨俭, 等. 含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的临床研究. 北方药学, 2016, 13(5):106-107. |
[26] |
张喜平, 肖攀云. 含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的效果. 临床医学研究与实践, 2019, 4(3):11-12. doi:10.19347/j.cnki.2096-1413.201903005.
doi: 10.19347/j.cnki.2096-1413.201903005 |
[27] | 肖海凤. 环丝氨酸联合胸腺肽肠溶片治疗耐多药肺结核的效果及对患者细胞免疫功能的影响. 中国现代医生, 2021, 59(16):68-71. |
[28] |
林武振. 环丝氨酸联合胸腺肽对耐多药肺结核患者痰菌阴转及细胞免疫功能的影响. 现代诊断与治疗, 2017, 28(22):4234-4236. doi:10.3969/j.issn.1001-8174.2017.22.077.
doi: 10.3969/j.issn.1001-8174.2017.22.077 |
[29] | 刘伯飞, 李昕, 赵丽, 等. 环丝氨酸联合胸腺肽对耐多药肺结核患者痰菌阴转及细胞免疫功能的影响分析. 中国保健营养, 2020, 30(10):350-351. |
[30] | 杨俭, 邱文超, 郭苏珊, 等. 环丝氨酸联合胸腺肽方案治疗耐多药肺结核的效果. 心电图杂志(电子版), 2018, 7(1):53-55. |
[31] | 韩红燕. 胸腺肽与含环丝氨酸方案在耐多药肺结核中的应用分析. 中外女性健康研究, 2022, 30(10):54-55,57. |
[32] | 周璐. 含环丝氨酸联合胸腺肽方案治疗耐多药肺结核的疗效分析. 人人健康, 2019, 38(8):249-250. |
[33] |
陈永宏, 向江琳, 肖江峰, 等. 环丝氨酸联合胸腺肽治疗耐多药肺结核的效果. 中华医院感染学杂志, 2019, 28(17):2643-2647. doi:10.11816/cn.ni.2019-182682.
doi: 10.11816/cn.ni.2019-182682 |
[34] |
王琳琳. 环丝氨酸辅助治疗MDR-TB的效果及安全性. 中国现代药物应用, 2020, 14(23):204-206. doi:10.14164/j.cnki.cn11-5581/r.2020.23.094.
doi: 10.14164/j.cnki.cn11-5581/r.2020.23.094 |
[35] |
邹广顺. 探讨环丝氨酸联合抗结核药物对耐多药肺结核的应用价值. 黑龙江医药, 2018, 31(5):1017-1019. doi:10.14035/j.cnki.hljyy.2018.05.033.
doi: 10.14035/j.cnki.hljyy.2018.05.033 |
[36] |
曹海峰, 李剑波. 环丝氨酸替代对氨基水杨酸钠治疗耐多药肺结核临床应用分析. 世界最新医学信息文摘, 2017, 17(85):114. doi:10.19613/j.cnki.1671-3141.2017.85.083.
doi: 10.19613/j.cnki.1671-3141.2017.85.083 |
[37] |
陈春玲. 环丝氨酸替代对氨基水杨酸钠治疗耐多药肺结核患者的临床疗效. 医疗装备, 2018, 31(18):82-83. doi:10.3969/j.issn.1002-2376.2018.18.059.
doi: 10.3969/j.issn.1002-2376.2018.18.059 |
[38] |
裴洁, 银春莲, 覃伟, 等. 联用环丝氨酸在耐多药肺结核治疗中的疗效及安全性研究. 传染病信息, 2015, 28(4):237-240. doi:10.3969/j.issn.1007-8134.2015.04.013.
doi: 10.3969/j.issn.1007-8134.2015.04.013 |
[39] | 明磊. 环丝氨酸联合抗结核药物治疗耐多药肺结核的有效性及安全性. 临床医药文献电子杂志, 2020, 7(8):90. |
[40] |
谢舒枝, 曹廷智, 曾剑锋, 等. 环丝氨酸与抗结核药物联合治疗耐多药肺结核的疗效及安全性探析. 中国实用医药, 2018, 13(17):129-131. doi:10.14163/j.cnki.11-5547/r.2018.17.067.
doi: 10.14163/j.cnki.11-5547/r.2018.17.067 |
[41] | 邹洪强. 环丝氨酸辅助治疗耐多药肺结核的疗效观察. 现代诊断与治疗, 2021, 32(4):529-531. |
[42] |
彭章丽, 闫静. 环丝氨酸在治疗耐多药结核病中疗效及不良反应的分析. 临床医药文献电子杂志, 2018, 5(54):133. doi:10.3877/j.issn.2095-8242.2018.54.114.
doi: 10.3877/j.issn.2095-8242.2018.54.114 |
[43] |
沈莉莉. 环丝氨酸治疗耐多药结核病的临床治疗效果. 中国生化药物杂志, 2017, 37(11):193-194,197. doi:10.3969/j.issn.1005-1678.2017.11.083.
doi: 10.3969/j.issn.1005-1678.2017.11.083 |
[44] |
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data Meta-analysis. Lancet, 2018, 392(10150):821-834. doi:10.1016/S0140-6736(18)31644-1.
doi: S0140-6736(18)31644-1 pmid: 30215381 |
[45] |
汤玲玲, 陈丹萍, 方雪娥, 等. 耐药肺结核患者领悟社会支持的影响因素研究. 中国防痨杂志, 2020, 42(6):604-608. doi:10.3969/j.issn.1000-6621.2020.06.012.
doi: 10.3969/j.issn.1000-6621.2020.06.012 |
[46] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001 |
[47] |
Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis, 2021, 5:688-694. doi:10.1016/j.ijid.2021.03.001.
doi: 10.1016/j.ijid.2021.03.001 |
[48] |
Chirehwa MT, Court R, de Kock M, et al. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrob Agents Chemother, 2020, 64(11):e01381-20. doi:10.1128/AAC.01381-20.
doi: 10.1128/AAC.01381-20 |
[49] |
Reddy P. Preventing Vitamin B6-Related Neurotoxicity. Am J Ther, 2022, 29(6):e637-e643. doi:10.1097/MJT.0000000000001460.
doi: 10.1097/MJT.0000000000001460 pmid: 36608063 |
[50] |
Lowther J, Yard BA, Johnson KA, et al. Inhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivation. Mol Biosyst, 2010, 6(9):1682-1693. doi:10.1039/c003743e.
doi: 10.1039/c003743e pmid: 20445930 |
[1] | Yang Chao, Wang Jing, Tang Guilin, Geng Yang. Analysis of epidemiological characteristics and treatment outcomes of pulmonary tuberculosis patients in floating population in Tongzhou District of Beijing, 2012—2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 594-600. |
[2] | Lai Min, Wu Guihui, Chen Hongde, Cheng Yao, Luo Haixia, He Kejing. Clinical characteristics and maternal and infant outcomes of 13 pregnant women with rifampicin resistant and multidrug resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 412-419. |
[3] | Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie. Progress on short-course regimens for the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317. |
[4] | Xu Jing, Jiang Shuangshuang, Zheng Hailun, Luo Ping. Analysis of drug resistance characteristics and treatment outcomes of 290 patients with high risk of drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 323-327. |
[5] | Xu Yinjuan, Zhao Guolian, Cui Xiaoli, Dang Liyun, Kang Lei, Zhou Yong. The application value of SAT-TB in monitoring the curative effect of patients with tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 79-84. |
[6] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
[7] | Zhao Yidi, Zhang Tongqiang, Liu Fujun, Xu Yongshen, Guo Wei. Study on the efficacy and safety of CO2 cryotherapy combined with forceps in the treatment of lymph node fistula tracheobronchial tuberculosis in infants [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 827-834. |
[8] | YU Chun-hong, LIU Xing, SHEN Ling-jun, LI Hai-wen, LI Xie, WU Rong-shuang, LI Xian-rui, FAN Hao. Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 660-668. |
[9] | DONG Zhao-liang, YAO Li-ming, WANG Lian-bo, JIA Chen-guang, YAO Xiao-wei, LIU Shu-ren, LIU Feng-sheng, WANG Shuai. Analysis of effectiveness of short-course preoperative chemotherapy in rapid recovery of patients with single-segment spinal tuberculosis anterior surgery [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 559-564. |
[10] | LI Zhi-wei, LAI Keng, LI Tie-gang, LIANG Zi-chao, DU Yu-hua, ZHANG Jin-xin. Analysis of adverse treatment outcomes and influencing factors of drug-resistant tuberculosis patients in Guangzhou from 2016 to 2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 600-607. |
[11] | Zhou Qian, Deng Guofang, Wang Qingwen. Retrospective analysis of clinical intervention and follow-up of patients with systemic lupus erythematosus complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1294-1302. |
[12] | Li Shuolan, Li Mingwu, Li Guangmei, Wang Lin, Wan Rong, Ma Meng. Influencing factors of getting unfavorable treatment outcomes of patients with multidrug-resistant pulmonary tuberculosis in China: a Meta-analysis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1303-1313. |
[13] | Muradil·Mardan , Parhat·Yasin , Xu Tao, Cai Xiaoyu, Yakup·Abliz , Xun Chuanhui, Sheng Weibin, Mardan·Mamat . Meta-analysis of operation combined with irrigation and drainage of focus lesion in the treatment of spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1314-1320. |
[14] | Jin Long, Wang Lihua, Zhang Xiaolei, Jiang Huailong, Li Xiaonan, Liu Yuqin. Efficacy and safety of modified all-oral short course chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1321-1326. |
[15] | Chen Qifu, Zhang Shengkun, Liao Guangsheng, Tang Zhong, Zhan Shenlin, Deng Guofang, Zhang Peize, Chu Ming. Clinical effect on the treatment of long tunnelled external ventricular drainage for tuberculous meningitis complicated with hydrocephalus [J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1187-1192. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||